Member Info for RayPointer

The guy in the black tee-shirt, I just want to know what was in his coffee 😂

Yeah, but those two guys had done zero research on the Immunobody platform and how it works

Johnny, that is a good summary of where Scancell find themselves at present.

It's worth repeating:

STRONGEST CANCER VACCINE SIGNAL IN 10 YEARS

I just thought I would top up my SIPP 😂

Desouzaa

It is likely that the PFS gap between SOC and iSCIB1+ will grow even further. CPIs do not have a memory response whereas iSCIB1+ does.

Those memory TCells are stopping growth of the cancer at the very least in most patients.

30+ percentage difference to current SOC PFS.

The memory TCells are making a real difference.

According to Phil, iSCIB1+ scored better than SCIB1 for PFS because of the addition of Avidimab which increased the memory effect.

We are focused on the Scope trial at present, but what price Avidimab in the future.

With at least 1 Glymab possibly entering a clinical trial soon, we may soon see some more evidence of the value of Avidimab. Remember Lindy has always claimed that Avidimab has the potential to increase the efficacy of any mAb.

Https://en.wikipedia.org/wiki/Investigational_New_Drug

Pater, make yourself useful and ask ME for a CLX progress report on each of the 5 items listed below.

"The IND application may be divided into the following categories:

1) Preclinical testing consists of animal pharmacology and toxicology studies to assess whether the drug is safe for testing in humans. Also included are any previous experience with the drug in humans (often foreign use).

2) Manufacturing Information includes composition, manufacturer, and stability of, and the controls used for, manufacturing the drug. Used to ensure that the company can adequately produce and supply consistent batches of the drug.

3) Investigator information on the qualifications of clinical investigators, that is, the professionals (generally physicians) who oversee the administration of the experimental drug to the study subjects. Used to assess whether the investigators are qualified to fulfill their clinical trial duties.

4)Clinical trial protocols are the centerpiece of the IND. Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will expose the subjects to unnecessary risks.

5) Other commitments are commitments to obtain informed consent from the research subjects, to obtain a review of the study by an institutional review board (IRB), and to adhere to the investigational new drug regulations."

The list of bullet points has now come of age. 21 to be exact.

The fact that David Schilansky has been appointed interim CFO does strongly suggest he has been put in place to support one or more specific transactions.

Redmile are obviously heavily involved in this decision, so they will have a specific plan in mind for David's role.

I suspect a Nasdaq listing is the top of the agenda to possibly provide the funding for the phase 3 scope trial. Have Scancell decided to go it alone for this trial or are they hedging their bets? Only time will tell.

Oh, and good luck to Torquay United in their quest for glory.

I can't confirm this one way or the other, rats.

However, we have seen several references to attempts at solving the delivery problem. The latest is a very recent RNS dated 26th Mar 2026.

https://www.lse.co.uk/rns/VAL/valirx-commercial-update-q1-2026-tv63t77m52v51fc.html

"ValiRx has partnered with the University of Nottingham, providing in kind support for a recent £24,875 grant awarded through the University's Impact Acceleration Account (IAA) to support a 6-month feasibility program which will test feasibility and industrial relevance for a novel delivery platform for the Company's oncolytic peptide platform."

Only 1 rec for notoptalot!

Where have all the Val employees gone?

https://www.youtube.com/watch?v=ZgXNVA9ngx8

Scott Parker to manage them in the Championship (he's good at getting teams promoted) and then the bloke that sells the match-day pies will take over in the Premiership. Parker will then be pie-selling that season and also making sure the players are well stocked. That is the plan that the Burnley board are considering.

As for the odds of 1 million to one, well the Scancell SP is certain to hit £8 soon. Where does that leave the odds of Burnley winning the Premiership? However, what the bookies have not taken into account is the effect that all those pies will have on player performance.

No need to commiserate TF.

They'll be back after next season. Not sure about Tottenham though 😂

One thing seems obvious is that our Phil is not a great one for issuing RNSs.

I just wonder if he considers MHRA approval is not newsworthy after the FDA approval.

I think he has previously hinted that further approvals post FDA approval should be almost a formality

It's not good news when a trial fails.

However, let's see what the much vaunted, and twice postponed, Modi1 readout gives us for RCC.

It was at a conference just after a presentation by Lindy

Badsterman

You mention:

"Integrated Design of a Membrane-Lytic Peptide-Based Intravenous Nanotherapeutic Suppresses Triple-Negative Breast Cancer" - Published in Advanced Science (2022) regarding the CLX001 project."

"Development of membrane-active peptide therapeutics in oncology" - Published in the Journal of Peptide Science (2023), covering the development of CLX001."

Were Valirx involved in contributing to these two acticles?

I would say that the normal sequence of events is:

1) a biotech company develops ground-breaking science (this is obviously a long term process)

2) this is published and presented at conferences until such a time that the scientific community is seriously interested (this also can take a long time). This can take place in parallel with the development of the science.

3) only then do commercial people get seriously involved i.e. there is a definite product to sell and real interest in the product from scientists

Have any of Valirx's products reached stage 3? In other words, is there any evidence that pharma are keen on any of Valirx's products?

You've got to ask the question as to what exactly does Valirx bring to each of these partnerships?

One way of answering that question is to look at the scientific papers being published as a result of these partnerships.

Are there any?

Excellent post Notpot and heartily recommended.

On a more serious note, the other Mark has taken up the challenge to solve one of the great unsolved mysteries of physics. One that has baffled many great scientists including Einstein.

How can chopsticks be used to eat a custard pie?